Drug data last refreshed 49m ago · AI intelligence enriched 1mo ago
This is a fixed-dose combination tablet containing three nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs and NNRTIs): lamivudine, nevirapine, and stavudine. The combination is indicated for the treatment of HIV-1 infection in antiretroviral-naive and treatment-experienced patients. This regimen works by inhibiting HIV reverse transcriptase, blocking viral replication at an early stage of the infection cycle.
Pre-launch stage suggests active commercial planning and small cross-functional team assembly for market entry.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children
Roles on this product will center on launching a mature-class antiretroviral in underserved markets with existing generic competition. Career growth depends on market access strategy, geographic expansion, and operational excellence rather than blockbuster commercial potential.
Worked on LAMIVUDINE, NEVIRAPINE, AND STAVUDINE at Macleods Pharms? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.